Cancer Research Meeting Calendar Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reilly, R. T.
Right arrow Articles by Jaffee, E. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reilly, R. T.
Right arrow Articles by Jaffee, E. M.
[Cancer Research 61, 880-883, February 1, 2001]
© 2001 American Association for Cancer Research

Advances in Brief

The Collaboration of Both Humoral and Cellular HER-2/neu-targeted Immune Responses Is Required for the Complete Eradication of HER-2/neu-expressing Tumors1

R. Todd Reilly, Jean-Pascal H. Machiels, Leisha A. Emens, Anne M. Ercolini, Francesca I. Okoye, Rachel Y. Lei, Diane Weintraub and Elizabeth M. Jaffee2

Departments of Oncology [R. T. R., J-P. H. M., L. A. E., F. I. O., R. Y. L., E. M. J.] and Immunology [A. M. E., D. W., E. M. J.], The Johns Hopkins School of Medicine, Baltimore, Maryland 21231

HER-2/neu (neu) transgenic mice (neu-N mice), which express the nontransforming rat proto-oncogene, demonstrate immunological tolerance to neu that is similar to what is encountered in patients with neu-expressing breast cancer. We have shown previously that a significant increase in neu-specific T cells, but no induction of neu-specific antibody, is seen after neu-specific vaccination in neu-N mice. In contrast, a significant induction of both neu-specific T-cell and antibody responses is found in nontoleragenic FVB/N mice after vaccination. These mice are fully protected from a s.c. challenge with NT cells, a mammary tumor cell line derived from a spontaneous tumor that arose in a neu-N mouse, whereas neu-N mice are not. In this study, we demonstrate that CD4+ T cell-depleted FVB/N mice show no induction of neu-specific IgG after vaccination and are unable to reject an NT challenge (0 of 10 mice were tumor free). Conversely, the depletion of natural killer cells has no effect on vaccine-mediated tumor rejection (100% of mice were tumor free). In CD8+ T cell-depleted animals, where vaccine-induced neu-specific IgG titers were normal, NT growth was delayed, but only 10% of mice remained tumor free, demonstrating that neu-specific IgG alone is insufficient for protection from NT challenge. To directly assess the necessity for the combination of neu-specific cellular and humoral immune responses, severe combined immunodeficient mice were given an adoptive transfer of CTLs plus IgG derived from FVB/N mice. Animals that were given CTLs that recognized an irrelevant antigen plus neu-specific IgG developed tumors at a rate similar to CD8+ T cell-depleted FVB/N mice. Animals receiving an adoptive transfer of neu-specific CTLs plus control IgG derived from naive FVB/N mice were only partially protected from NT challenge (50% of animals were tumor free). However, only animals receiving the combination of neu-specific CTLs and neu-specific IgG were fully protected from NT challenge (100% of animals were tumor free). These studies specifically define the immunological requirements for the eradication of neu-expressing tumors in this model system, demonstrating that both cellular and humoral neu-specific responses are necessary for protection from an NT challenge. These data suggest that vaccines optimized to induce maximal T- and B-cell immunity to neu, and possibly to similar putative tumor-rejection antigens, may lead to more potent in vivo antitumor immunity.




This article has been cited by other articles:


Home page
 BloodHome page
C. Fonseca, R. Soiffer, V. Ho, M. Vanneman, M. Jinushi, J. Ritz, D. Neuberg, R. Stone, D. DeAngelo, and G. Dranoff
Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction
Blood, February 19, 2009; 113(8): 1681 - 1688.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Orlandi, F. M. Venanzi, A. Concetti, H. Yamauchi, S. Tiwari, L. Norton, J. D. Wolchok, A. N. Houghton, and P. D. Gregor
Antibody and CD8+ T Cell Responses against HER2/neu Required for Tumor Eradication after DNA Immunization with a Flt-3 Ligand Fusion Vaccine
Clin. Cancer Res., October 15, 2007; 13(20): 6195 - 6203.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. J. Czerniecki, G. K. Koski, U. Koldovsky, S. Xu, P. A. Cohen, R. Mick, H. Nisenbaum, T. Pasha, M. Xu, K. R. Fox, et al.
Targeting HER-2/neu in Early Breast Cancer Development Using Dendritic Cells with Staged Interleukin-12 Burst Secretion
Cancer Res., February 15, 2007; 67(4): 1842 - 1852.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Bracci, F. Moschella, P. Sestili, V. La Sorsa, M. Valentini, I. Canini, S. Baccarini, S. Maccari, C. Ramoni, F. Belardelli, et al.
Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration
Clin. Cancer Res., January 15, 2007; 13(2): 644 - 653.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. L. Knutson, H. Lu, B. Stone, J. M. Reiman, M. D. Behrens, C. M. Prosperi, E. A. Gad, A. Smorlesi, and M. L. Disis
Immunoediting of Cancers May Lead to Epithelial to Mesenchymal Transition
J. Immunol., August 1, 2006; 177(3): 1526 - 1533.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Ferrone and E. Ko
Collaboration is required for successful immunotherapy
Blood, April 15, 2006; 107(8): 3025 - 3026.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Peng, E. Ko, W. Luo, X. Wang, P. A. Shrikant, and S. Ferrone
CD4-Dependent Potentiation of a High Molecular Weight-Melanoma-Associated Antigen-Specific CTL Response Elicited in HLA-A2/Kb Transgenic Mice
J. Immunol., February 15, 2006; 176(4): 2307 - 2315.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Zhang, K. L. Knutson, K. E. Hellstrom, M. L. Disis, and I. Hellstrom
Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion
Mol. Cancer Ther., January 1, 2006; 5(1): 149 - 155.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. A. Laheru, D. M. Pardoll, and E. M. Jaffee
Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology
Mol. Cancer Ther., November 1, 2005; 4(11): 1645 - 1652.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. Singh, M. E. Dominiecki, E. M. Jaffee, and Y. Paterson
Fusion to Listeriolysin O and Delivery by Listeria monocytogenes Enhances the Immunogenicity of HER-2/neu and Reveals Subdominant Epitopes in the FVB/N Mouse
J. Immunol., September 15, 2005; 175(6): 3663 - 3673.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
N. C. Peterson, M. D. Servinsky, A. Christian, Z. Peng, W. Qiu, J. Mann, J. Dicello, and D. L. Huso
Tamoxifen resistance and Her2/neu expression in an aged, irradiated rat breast carcinoma model
Carcinogenesis, September 1, 2005; 26(9): 1542 - 1552.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. M. Park, M. Terabe, Y. Sakai, J. Munasinghe, G. Forni, J. C. Morris, and J. A. Berzofsky
Early Role of CD4+ Th1 Cells and Antibodies in HER-2 Adenovirus Vaccine Protection against Autochthonous Mammary Carcinomas
J. Immunol., April 1, 2005; 174(7): 4228 - 4236.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
L A Emens, R T Reilly, and E M Jaffee
Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity
Endocr. Relat. Cancer, March 1, 2005; 12(1): 1 - 17.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. B. Montgomery, E. Makary, K. Schiffman, V. Goodell, and M. L. Disis
Endogenous Anti-HER2 Antibodies Block HER2 Phosphorylation and Signaling through Extracellular Signal-Regulated Kinase
Cancer Res., January 15, 2005; 65(2): 650 - 656.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. L. Palomba, W. K. Roberts, T. Dao, G. Manukian, J. A. Guevara-Patino, J. D. Wolchok, D. A. Scheinberg, and A. N. Houghton
CD8+ T-Cell-Dependent Immunity Following Xenogeneic DNA Immunization against CD20 in a Tumor Challenge Model of B-Cell Lymphoma
Clin. Cancer Res., January 1, 2005; 11(1): 370 - 379.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. Nanni, L. Landuzzi, G. Nicoletti, C. De Giovanni, I. Rossi, S. Croci, A. Astolfi, M. Iezzi, E. Di Carlo, P. Musiani, et al.
Immunoprevention of Mammary Carcinoma in HER-2/neu Transgenic Mice Is IFN-{gamma} and B Cell Dependent
J. Immunol., August 15, 2004; 173(4): 2288 - 2296.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. De Giovanni, G. Nicoletti, L. Landuzzi, A. Astolfi, S. Croci, A. Comes, S. Ferrini, R. Meazza, M. Iezzi, E. Di Carlo, et al.
Immunoprevention of HER-2/neu Transgenic Mammary Carcinoma through an Interleukin 12-Engineered Allogeneic Cell Vaccine
Cancer Res., June 1, 2004; 64(11): 4001 - 4009.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. L. Disis, K. Schiffman, K. Guthrie, L. G. Salazar, K. L. Knutson, V. Goodell, C. dela Rosa, and M. A. Cheever
Effect of Dose on Immune Response in Patients Vaccinated With an HER-2/neu Intracellular Domain Protein--Based Vaccine
J. Clin. Oncol., May 15, 2004; 22(10): 1916 - 1925.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. I. Spiridon, S. Guinn, and E. S. Vitetta
A Comparison of the in Vitro and in Vivo Activities of IgG and F(ab')2 Fragments of a Mixture of Three Monoclonal Anti-Her-2 Antibodies
Clin. Cancer Res., May 15, 2004; 10(10): 3542 - 3551.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Quaglino, M. Iezzi, C. Mastini, A. Amici, F. Pericle, E. Di Carlo, S. M. Pupa, C. De Giovanni, M. Spadaro, C. Curcio, et al.
Electroporated DNA Vaccine Clears Away Multifocal Mammary Carcinomas in Her-2/neu Transgenic Mice
Cancer Res., April 15, 2004; 64(8): 2858 - 2864.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Kono, E. Sato, H. Naganuma, A. Takahashi, K. Mimura, H. Nukui, and H. Fujii
Trastuzumab (Herceptin) Enhances Class I-Restricted Antigen Presentation Recognized by HER-2/neu-Specific T Cytotoxic Lymphocytes
Clin. Cancer Res., April 1, 2004; 10(7): 2538 - 2544.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Herrmann, H.-A. Lehr, I. Drexler, G. Sutter, J. Hengstler, U. Wollscheid, and B. Seliger
HER-2/neu-Mediated Regulation of Components of the MHC Class I Antigen-Processing Pathway
Cancer Res., January 1, 2004; 64(1): 215 - 220.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. L. Disis, N. Scholler, A. Dahlin, J. Pullman, K. L. Knutson, K.-E. Hellstrom, and I. Hellstrom
Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity
Mol. Cancer Ther., October 1, 2003; 2(10): 995 - 1002.
[Abstract] [Full Text]

Home page
 JCOHome page
R. Soiffer, F. S. Hodi, F. Haluska, K. Jung, S. Gillessen, S. Singer, K. Tanabe, R. Duda, S. Mentzer, M. Jaklitsch, et al.
Vaccination With Irradiated, Autologous Melanoma Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor by Adenoviral-Mediated Gene Transfer Augments Antitumor Immunity in Patients With Metastatic Melanoma
J. Clin. Oncol., September 1, 2003; 21(17): 3343 - 3350.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. E. Wolpoe, E. R. Lutz, A. M. Ercolini, S. Murata, S. E. Ivie, E. S. Garrett, L. A. Emens, E. M. Jaffee, and R. T. Reilly
HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/neu-Transgenic Mice
J. Immunol., August 15, 2003; 171(4): 2161 - 2169.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
V. Renard, L. Sonderbye, K. Ebbehoj, P. B. Rasmussen, K. Gregorius, T. Gottschalk, S. Mouritsen, A. Gautam, and D. R. Leach
HER-2 DNA and Protein Vaccines Containing Potent Th Cell Epitopes Induce Distinct Protective and Therapeutic Antitumor Responses in HER-2 Transgenic Mice
J. Immunol., August 1, 2003; 171(3): 1588 - 1595.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Gnjatic, D. Atanackovic, E. Jager, M. Matsuo, A. Selvakumar, N. K. Altorki, R. G. Maki, B. Dupont, G. Ritter, Y.-T. Chen, et al.
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses
PNAS, July 22, 2003; 100(15): 8862 - 8867.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
F. S. Hodi, M. C. Mihm, R. J. Soiffer, F. G. Haluska, M. Butler, M. V. Seiden, T. Davis, R. Henry-Spires, S. MacRae, A. Willman, et al.
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
PNAS, April 15, 2003; 100(8): 4712 - 4717.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. M. Ercolini, J.-P. H. Machiels, Y. C. Chen, J. E. Slansky, M. Giedlen, R. T. Reilly, and E. M. Jaffee
Identification and Characterization of the Immunodominant Rat HER-2/neu MHC Class I Epitope Presented by Spontaneous Mammary Tumors from HER-2/neu-Transgenic Mice
J. Immunol., April 15, 2003; 170(8): 4273 - 4280.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. C. Schmollinger, R. H. Vonderheide, K. M. Hoar, B. Maecker, J. L. Schultze, F. S. Hodi, R. J. Soiffer, K. Jung, M. J. Kuroda, N. L. Letvin, et al.
Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction
PNAS, March 18, 2003; 100(6): 3398 - 3403.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Salgia, T. Lynch, A. Skarin, J. Lucca, C. Lynch, K. Jung, F. S. Hodi, M. Jaklitsch, S. Mentzer, S. Swanson, et al.
Vaccination With Irradiated Autologous Tumor Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor Augments Antitumor Immunity in Some Patients With Metastatic Non-Small-Cell Lung Carcinoma
J. Clin. Oncol., February 15, 2003; 21(4): 624 - 630.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Carter, D. C. Dillon, L. D. Reynolds, M. W. Retter, G. Fanger, D. A. Molesh, P. R. Sleath, P. D. McNeill, T. S. Vedvick, S. G. Reed, et al.
Serum Antibodies to Lipophilin B Detected in Late Stage Breast Cancer Patients
Clin. Cancer Res., February 1, 2003; 9(2): 749 - 754.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. M. Krackhardt, M. Witzens, S. Harig, F. S. Hodi, A. J. Zauls, M. Chessia, P. Barrett, and J. G. Gribben
Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX
Blood, August 28, 2002; 100(6): 2123 - 2131.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. I. Spiridon, M.-A. Ghetie, J. Uhr, R. Marches, J.-L. Li, G.-L. Shen, and E. S. Vitetta
Targeting Multiple Her-2 Epitopes with Monoclonal Antibodies Results in Improved Antigrowth Activity of a Human Breast Cancer Cell Line in Vitro and in Vivo
Clin. Cancer Res., June 1, 2002; 8(6): 1720 - 1730.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
F. S. Hodi, J. C. Schmollinger, R. J. Soiffer, R. Salgia, T. Lynch, J. Ritz, E. P. Alyea, J. Yang, D. Neuberg, M. Mihm, et al.
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction
PNAS, May 14, 2002; 99(10): 6919 - 6924.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. P. Piechocki, S. A. Pilon, and W.-Z. Wei
Complementary Antitumor Immunity Induced by Plasmid DNA Encoding Secreted and Cytoplasmic Human ErbB-2
J. Immunol., September 15, 2001; 167(6): 3367 - 3374.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.